Assessment and Management of Cardiotoxicity in Hematologic Malignancies

被引:24
作者
Bojan, Anca [1 ,2 ]
Torok-Vistai, Tunde [1 ,2 ]
Parvu, Andrada [1 ,2 ]
机构
[1] Ion Chiricuta Oncol Inst, Cluj Napoca, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Cluj Napoca, Romania
关键词
D O I
10.1155/2021/6616265
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
With the increasing overall survival of cancer patients due to recent discoveries in oncology, the incidence of side effects is also rising, and along with secondary malignancies, cardiotoxicity is one of the most concerning side effects, affecting the quality of life of cancer survivors. There are two types of cardiotoxicity associated with chemotherapy; the first one is acute, life-threatening but, fortunately, in most of the cases, reversible; and the second one is with late onset and mostly irreversible. The most studied drugs associated with cardiotoxicity are anthracyclines, but many new agents have demonstrated unexpected cardiotoxic effect, including those currently used in multiple myeloma treatment (proteasome inhibitors and immunomodulatory agents), tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia and some forms of acute leukemia, and immune checkpoint inhibitors recently introduced in treatment of refractory lymphoma patients. To prevent irreversible myocardial damage, early recognition of cardiac toxicity is mandatory. Traditional methods like echocardiography and magnetic resonance imaging are capable of detecting structural and functional changings, but unable to detect early myocardial damage; therefore, more sensible biomarkers like troponins and natriuretic peptides have to be introduced into the current practice. Baseline assessment of patients allows the identification of those with high risk for cardiotoxicity, while monitoring during and after treatment is important for early detection of cardiotoxicity and prompt intervention.
引用
收藏
页数:10
相关论文
共 45 条
[1]   Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies [J].
Al-Rubaye, Aws Sabah ;
Noori, Ahmed S. ;
Saleh, Tareq Abdullah ;
Ibrahim, Ibrahim Khalil .
IRAQI JOURNAL OF HEMATOLOGY, 2019, 8 (02) :63-68
[2]   Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines [J].
Alexandre, Joachim ;
Cautela, Jennifer ;
Ederhy, Stephane ;
Damaj, Ghandi Laurent ;
Salem, Joe-Elie ;
Barlesi, Fabrice ;
Farnault, Laure ;
Charbonnier, Aude ;
Mirabel, Mariana ;
Champiat, Stephane ;
Cohen-Solal, Alain ;
Cohen, Ariel ;
Dolladille, Charles ;
Thuny, Franck .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (18)
[3]   Growth-differentiation factor-15 and tissue doppler imaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors [J].
Arslan, Derya ;
Cihan, Tugba ;
Kose, Dogan ;
Vatansev, Husamettin ;
Cimen, Derya ;
Koksal, Yavuz ;
Oran, Bulent ;
Akyurek, Fikret .
CLINICAL BIOCHEMISTRY, 2013, 46 (13-14) :1239-1243
[4]   Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) [J].
Bringhen, Sara ;
Milan, Alberto ;
Ferri, Claudio ;
Waesch, Ralph ;
Gay, Francesca ;
Larocca, Alessandra ;
Salvini, Marco ;
Terpos, Evangelos ;
Goldschmidt, Hartmut ;
Cavo, Michele ;
Petrucci, Maria Teresa ;
Ludwig, Heinz ;
Auner, Holger W. ;
Caers, Jo ;
Gramatzki, Martin ;
Boccadoro, Mario ;
Einsele, Hermann ;
Sonneveld, Pieter ;
Engelhardt, Monika .
HAEMATOLOGICA, 2018, 103 (09) :1422-1432
[5]   Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy [J].
Cardinale, D ;
Sandri, MT ;
Colombo, A ;
Colombo, N ;
Boeri, M ;
Lamantia, G ;
Civelli, M ;
Peccatori, F ;
Martinelli, G ;
Fiorentini, C ;
Cipolla, CM .
CIRCULATION, 2004, 109 (22) :2749-2754
[6]   Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy [J].
Cardinale, Daniela ;
Colombo, Alessandro ;
Bacchiani, Giulia ;
Tedeschi, Ines ;
Meroni, Carlo A. ;
Veglia, Fabrizio ;
Civelli, Maurizio ;
Lamantia, Giuseppina ;
Colombo, Nicola ;
Curigliano, Giuseppe ;
Fiorentini, Cesare ;
Cipolla, Carlo M. .
CIRCULATION, 2015, 131 (22) :1981-1988
[7]   Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities [J].
Chaar, Maher ;
Kamta, Jeff ;
Ait-Oudhia, Sihem .
ONCOTARGETS AND THERAPY, 2018, 11 :6227-6237
[8]   Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity [J].
Christenson, Eric S. ;
James, Theodore ;
Agrawal, Vineet ;
Park, Ben H. .
CLINICAL BIOCHEMISTRY, 2015, 48 (4-5) :223-235
[9]   Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity [J].
Civelli, Maurizio ;
Cardinale, Daniela ;
Martinoni, Alessandro ;
Lamantia, Giuseppina ;
Colombo, Nicola ;
Colombo, Alessandro ;
Gandini, Sara ;
Martinelli, Giovanni ;
Fiorentini, Cesare ;
Cipolla, Carlo M. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 111 (01) :120-126
[10]   Adverse effects of thalidomide administration in patients with neoplastic diseases [J].
Dimopoulos, MA ;
Eleutherakis-Papaiakovou, V .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 (07) :508-515